Yunbin Zhong1†Haibo Li2†Peiwen Li2Yong Chen3Mengyao Zhang2Zhendong Yuan1Yufang Zhang4Zhijie Xu5Geng Luo1
Yuan Fang2,6*‡Xu Li2*‡- 1Hand, Foot Vascular Surgery, Tungwah Hospital to Sun Yet-sen University, Dongguan, China
- 2Department of Plastic Surgery, The Third Xiangya Hospital, Central South University, Changsha, China
- 3Dermatology Department, The First Hospital of Changsha, Changsha, China
- 4Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang, China
- 5Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
- 6Department of Plastic and Reconstructive Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Exosomes are extracellular vesicles (EVs) that are secreted into body fluids by multiple cell types and are enriched in bioactive molecules, although their exact contents depend on the cells of origin. Studies have shown that exosomes in the tumor microenvironment affect tumor growth, metastasis and drug resistance by mediating intercellular communication and the transport of specific molecules, although their exact mechanisms of action need to be investigated further. In this review, we have summarized current knowledge on the relationship between tumor drug resistance and exosomes, and have discussed the potential applications of exosomes as diagnostic biomarkers and therapeutic targets.
Introduction
Exosomes were discovered by Pan et al. while studying the transition of reticulocytes to mature red blood cells (1), and were later defined by Johnstone et al. as vesicles that containing non-essential proteins that are expelled from cells (2) following the fusion of microvesicles with the cell membranes (3). Subsequent studies showed that exosomes are released from blood cells, tumor cells, epithelial cells, mesenchymal stem cells and neuronal cells into the blood, saliva, urine and other body fluids (4–7). Exosomes were first considered to be “garbage bags” that remove waste proteins and metabolites. However, recent studies have shown that the exosomal cargo is biologically active (8) and mediates intercellular communication (9). Several exosomes-enriched proteins, including cytoskeletal proteins, fusion-related proteins, tetrapeptides (CD9, CD63, CD81 and CD82) and membrane connectins (10, 11), as well as oncoproteins (12), have been reported on in recent years. Furthermore, exosomes are also known to transport nucleic acids, such as DNA and coding and non-coding RNAs (13), including micro RNAs (miRNAs) and circular RNAs (circRNAs) (14), that regulate various aspects of tumor development, including immunosuppression, angiogenesis, cell migration and invasion (15–17). Electron microscopy studies have revealed that exosomes measure 50-150 nm in diameter and have a “dish-like” or “cup-shaped” morphology. In addition, several surface exosomal proteins, such as the lysosomal protein Lamp2b, heat shock protein Hsp70 and others (18, 19) that serve as diagnostic markers have also been identified.
Chemotherapeutic drug resistance is a major challenge in cancer treatment. Tumor cells are either naturally resistant to drugs or acquire resistance over the course of treatment (20). Acquired drug resistance is the result of mutations, polymorphisms and splicing variations in genes related to drug metabolism and toxicity (21). A major mechanism of drug resistance in tumor cells is the overexpression of membrane transporters, in particular the ATP binding box (ABC) transporter protein, which rapidly expel drugs and thus reduces their intracellular levels. Furthermore, mutations in drug targets can decrease the efficacy and toxicity of drugs. Interestingly, studies have shown that exposure to chemotherapy drugs significantly increases mutation rates in cancer cells, which may be partially attributed to the activation of pro-survival and anti-apoptotic pathways (22). Furthermore, tumor cells have a higher DNA repair rate compared with normal cells, which neutralizes any DNA damage induced by chemotherapeutic drugs and generates drug-resistant clones. Given that exosomes are involved in the aforementioned signaling pathways, it is important to explore their role in the development of drug resistance (23). In this review, we have summarized the common mechanisms of the genesis of chemoresistance in cancer cells and have also discussed the possible involvement of exosomes.
Exosomal-Mediated Tumor Resistance
Exosomes Participate in Tumor Microenvironment Regulation
The tumor microenvironment (TME) is comprised of fibroblasts, stromal cells and the extracellular matrix that aid in the survival, proliferation and metastasis of tumor cells (24, 25). Exosomes mediate cell-to-cell communication in the TME by shuttling signaling molecules, lipids, proteins, nucleic acids and metabolites. In addition, exosomes released from the tumor cells and stromal cells can regulate drug resistance by directly interacting with drug molecules, altering the transcriptome of cancer cells and influencing the immune response (26). The extracellular acidity of tumors markedly affects exosome release by tumors in terms of both the amounts of released exosomes and the make-up of the exosomes (27–30). As shown in Figure 1 (31), exosomes release active molecules, such as ncRNAs and proteins into target cells following receptor ligand interactions, membrane fusion, as well as puffing, phagocytosis, or receptor-mediated endocytosis, which then regulates tumor cell proliferation, invasion, metastasis and drug resistance (32, 33).
Figure 1 Exosomes in the tumor microenvironment mainly complete information exchange and material transportation between tumor cells.
Tumor cells induce adaptive changes in distant organs to create a “pre-metastatic” environment that is conducive to their growth, and the formation of the secondary metastatic foci (34). Zhou et al. showed that exosomes derived from highly metastatic breast cancer cells express high levels of miR-105 (35). Absorption of these exosomes by pulmonary microvascular endothelial cells leads to the significant downregulation of ZO-1, which increases vascular permeability and facilitates the colonization of lung tissues by the tumor cells. Likewise, Yu et al. found that tumor cell-derived exosomes induced the formation of a pre-metastatic niche in the liver of a mouse model of pancreatic cancer, which enhanced metastasis and primary tumor growth. In addition, Costa-Silva et al. found that pancreatic cancer cells release exosomes loaded with macrophage migration inhibitory factors that are absorbed by the hepatic Kupffer cells. This promotes TGF-βD secretion and up-regulates the fibronectin level, and increases the metastasis of tumor cells to the liver. Evidence also indicates that the TME plays a role in drug resistance (36, 37). PGP transported by exosomes can fuse with the plasma membrane of osteosarcoma cells, and P-glycoprotein (P-gp) transporters that enrich tumor cells, resulting in pharmacological desensitization (38). In addition, exosomal P-gp in the serum of prostate cancer patients is a potential biomarker of docetaxel resistance (39).
Exosomes Participate in Tumor Local Immune Microenvironment Regulation
The TME harbors multiple immune cells including T lymphocytes, neutrophils, NK cells and the tumor-associated macrophages (TAMs). The T cells and TAMs in particular play a significant role in tumor genesis, development and drug resistance, while exosomes in the TME for instrumental in the interactions between immune cells and cancer cells. Exosomes released by the CD8+ T cells contain O-GlcNAc transferase, which upregulates PD-1 in the recipient cells and creates an immunosuppressive environment (40). Previous studies have shown that cancer cell-derived exosomes not only promote anti-tumor immunity but also enhance tumor immune escape (41). Binenbaum et al. demonstrated that when macrophage-derived exosomes expressing miR-365 are internalized by pancreatic ductal adenocarcinoma (PDAC) cells, the tri-phospho-nucleotide pool in cancer cells increases and activates cytidine deaminase, which then inducing resistance to gemcitabine (42).
Signal Transmission Between Drug-Resistant Cells and Sensitive Cells
Given the highly heterogeneous nature of tumors, individual cells of the same tumor mass differ in their response to chemotherapeutic drugs. Interestingly, chemoresistance or chemosensitivity can be transferred between cells via exosomes (see Table 1). For instance, exosomes derived from cisplatin-resistant lung cancer cells induced drug resistance in recipient cells via miRNA-100-5p, which altered mTOR expression levels (43). Fu X et al. showed that multidrug-resistant liver cells transferred miRNA-32-5p to sensitive cells through exosomes, which then activated phosphatidylinositol kinase via the protein kinase B (Akt) pathway and induced drug resistance (44). Compared with chemo-sensitive breast cancer cell lines such as MCF-7, the resistant strains express significantly higher levels of miRNA-222. The exosomes secreted by azithromycin-resistant breast cancer cells can confer drug resistance to sensitive recipient cells via miR-222, which is known to regulate cell cycle and apoptosis-related genes (45). Zhang et al. showed that colon cancer cells-derived exosomes promoted cetuximab resistance by downregulating human chromosome 10 phosphatase (PTEN) and increasing phosphorylated Akt levels (46). Furthermore, the exosomes released by gemcitabine-resistant cancer cells delivered miRNA-222-3p to recipient cells through endocytosis, which promote drug resistance and malignant progression by targeting SOCS3 (47). Takahashi et al. found that sorafenib-resistant liver cancer cells expressed high levels of the lncRNA RoR that modulates the TGF-β signaling pathway. Furthermore, the co-culture of sensitive liver cancer cells with lncRNA-RoR exosomes released by drug-resistant cells was able to induce sorafenib resistance (48). Qu et al. found that exosomal lncARSR induced sunitinib resistance in renal cancer cells by sponging miR-34 and miR-449 and upregulating receptor tyrosine kinase (AXL) and c-MET (49).
Table 1 Signal transmission between drug-resistant cells and sensitive cells.
Signal Transmission Between Stromal Cells and Tumor Cells
Exosomes derived from stromal cells can also induce drug resistance (Table 2). Zheng et al. showed that exosomes derived from M2 macrophages conferred cisplatin resistance to gastric cancer cells through miRNA-21, which inhibited apoptosis by downregulating PTEN and activating the PI3K/Akt signaling pathway (50, 55). Likewise, Ji et al. found that exosomes derived from mesenchymal stem cells (MSCs) induced fluorouracil resistance in gastric cancer cells by activating the CaMKs/Raf/MEK/ERK pathway (51). In addition, exosomes secreted by bone marrow matrix cells induced bortezomib resistance in myeloma cells (52), whereas colon tumors in mice developed resistance to fluorouracil or oxaliplatin in the presence of fibroblast-derived exosomes (53). Boelens et al. found that matrix cells in breast tumors trigger drug resistance in a paracrine manner through exosomal RNAs that activate the NOTCH3 signaling pathway (54).
Table 2 Signal transmission between stromal cells and tumor cells.
As shown through the introduction to this section, exosomes play an important role in various types of transmissions, including the transmission of cisplatin and therapeutic antibodies (56–58). Exosomes with functional enzyme molecules can also be detected in human plasma and may play a pivotal guiding role in cancer progression (59). Exosomes carry molecules with the dual functions of being tracers and therapeutic molecules indicating their diagnostic and therapeutic potential (57). Exosomes are involved in regulating the direction material movement. Recently, researchers have also used exosomes to transfer nano materials (60). Therefore, the potential applications of exosomes are not only limited to its role in the development of tumor drug resistance.
The Role And Mechanism of Action of Exosomes in the Development of Tumor Resistance
Regulation of Neoplastic Growth and Metastasis
Cancer stem cells (CSCs) are the source of primary and metastatic tumors, as well as the basis of chemo- and radio-resistance, which leads to tumor recurrence (61). Studies have shown that CSCs often reappear after chemotherapy and express the ATP binding cassette subfamily B member 5 (ABCB5) protein, which mediates multidrug resistance in multiple cancers. The stem cell-derived exosomes express pluripotency-related transcription factors such as Nanog, Oct-4, HOXB4, Rex-1, and Wnt-3, which can endow recipient cells with “stemness” features, such as self-renewal, expansion and differentiation into progenitor cells (62). In addition, exosomes secreted by the cancer-associated fibroblasts (CAFs) express Snail1, which can induce the epithelial-mesenchymal transition of recipient lung cancer cells (63). A recent study showed that tumor cells cultured in a conditioned medium of CAFs showed a higher proliferation rates in the presence of 5-fluorouracil or oxaliplatin, compared with cells grown in normal culture medium (53). Thus, drugs that target the CAFs can potentially sensitize tumor cells to chemotherapy. Furthermore, exosomes secreted by CSCs promote tumor growth and metastasis through paracrine and endocrine modes. The inhibition of exosome secretion can slow clonal expansion and tumor growth (64).
Expression of Transcription Factors
MiR-210 is expressed at significantly higher levels in colorectal cancer (CRC) tissues compared with that of normal colon tissues, and is associated with an increased level of metastasis. The exosomes secreted by the primary CRC cell line, HCT-8, induced 5-fluorouracil and folate resistance in the chemo-sensitive cells by delivering miR-210, which significantly increased sib levels (65). Non-small cell lung cancer (NSCLC) is usually of one of two types, either chemotherapeutic resistance or tumor rapid metastasis and spread. It is generally believed that this resistance is caused by mesenchymal NSCLC cells, but the mechanism of metastasis is unclear. R. J. et al. suggested that exosomes release by these transformed mesenchymal phenotype cancer cells could induce drug resistance in parental EPC and increased the expression of ZEB1 mRNA in receptor cells (66). Furthermore, T cell-derived exosomes triggered the epithelial mesenchymal transition (EMT) of esophageal cancer cells (67), and the exosomes released from CAFs promoted cancer cell growth and EMT via miR-21, miR-378e and miR-143 (68).
Cell Cycle and Apoptosis
MiR-21 is transferred from resident fat cells or fibroblasts in ovarian tumors to the cancer cells, and can induce drug resistance by inhibiting APAF1-mediated apoptosis (69). In addition, the exosomes secreted by the M2 polarized macrophages can induce cisplatin resistance in gastric cancer cells by directly delivering miR-21 into the recipient cells (50). Furthermore, Her2+ breast cancer cells-derived exosomes can promote trastuzumab resistance via lncSNHG14 that targets the Bcl-2/BAX apoptotic pathway (70). The PLX-4720 BRAF inhibitor–resistant melanoma cells were able to activate of PI3K/AKT signaling and inhibition of the MAPK pathway (71). A recent study showed that exosomes containing miR-32-5p induced multi-drug resistance by activating the PI3K/AKT pathway and inhibiting PTEN (44).
Drug Efflux and Metabolism
The concentration of drugs used for the treatment of cancer cells can be reduced to therapeutically sub-optimal levels by decreasing its permeability through the cell membrane and/or increasing its active efflux. L.V. et al. found that exosomes can efficiently transfer p-glycoprotein (p-gp) from chemo-resistant breast cancer cells to sensitive cells, thus inducing resistance in the latter through increased drug efflux (72). Based on these findings, p-gp was hypothesized to be a drug efflux pump encoded by the ABCB1 gene (73). The experiment conducted by L.V. et al. indicated that when adding MCF-7/DOC that extract of supernatant fluid secretion body (DOC/exobiology) for culture, MCF-7/S resistance can be induced, and to join the MCF-7/S exosomes (S/exobiology) training, MCF-7/S did not acquire resistance. When MCF-7/S and DOC/exo was co-cultured, the level of p-glycoprotein expression raised based on the number of exosomes. Similar to the finding of the above mentioned studies, Ning et al. confirmed that exosomes secreted by MCF7/ADM carried UCH-L1 and p-glycoprotein (74). Taken together, the above mentioned findings indicate that drug-resistant breast cancer cells can secrete exosomes containing p-gp, and confer chemoresistance to the more sensitive recipients. The exosomes secreted by the docetaxel-sensitive DU145 prostate cancer cells (DU145 tax-sen) are enriched in MDR1 (ABCB1), mdr-3, endophilin-a2, and PABP4, which are potential biomarkers of docetaxel resistance (75).
In conclusion, exosomes secreted by tumor related cells can promote tumor growth and metastasis through a variety of action pathways. At the same time, some small RNA molecules can affect cell apoptosis, so as to achieve the effect of drug resistance. If the exosome carrier is no longer small RNA, but a drug, it can induce drug resistance in the process of endocytosis and exocytosis. The ability of exosomes to repair DNA or block the process of transferring mRNA can increase the sensitivity of chemotherapy and radiotherapy and achieve better therapeutic effect.
The Role of Exosomes in Tumor Drug Resistance
Based on the available research, exosomes have shown to be promising nanocarriers that can be used for the reversal of tumor drug resistance. For instance, Wang et al. sensitized cisplatin-resistant gastric cancer cells by directly delivering anti-miRNA-214 to the recipient cells through exosomes (76). Rapamycin and U18666A can sensitize B lymphoma cells to rituximab via the inhibition of exosome release by interfering with the synthesis of MVBs and the incorporation of cholesterol into cell membranes. Some researchers have found that β-elemene can act on targeted genes in breast cancer cell lines to alter the expression of resistance-related miRNAs in exosomes, thereby reducing the level of resistance transmission through exosomes and enhancing the sensitivity to chemotherapy (77) (see Figure 2).
Figure 2 The role of exosomes in the treatment of tumor drug resistance.
Targeting Exosomes to Reverse Chemoresistance
In recent years, several studies have demonstrated that exosomes can be targeted to prevent the development and reverse the chemoresistance of cancer cells. For instance, Cao et al. showed that the neutral sphingomyelinase (NSM) inhibitor, GW4869, sensitized cisplatin-resistant ovarian cancer cells, indicating the therapeutic potential of this novel drug in the recalcitrant cancer patients (78). Furthermore, studies have shown that ketotifen, cannabinol (CBD) and psoralen can sensitize tumor cells to chemotherapeutic drugs by reducing exosome secretion from these cells. Likewise, rhamnose-emodin can reduce exosome secretion from the doxorubicin-resistant breast cancer cells and downregulate the expression of exosomal miRNAs involved in chemoresistance, reversing drug resistance. The exosomes secreted by human umbilical cord mesenchymal cells (hUC-MSC-Exo) can sensitize myelogenous leukemia K562 cells to imatinib by activating the caspase signaling pathway (79). Therefore, the combination of imatinib and hUC-MSC-Exo is a promising therapeutic strategy against chronic myelogenous leukemia (CML) (79). Li et al. found that the exosome-specific miRNA-770 reversed doxorubicin resistance in triple negative breast cancer (TNBC) cells by regulating apoptosis pathways and the TME (80). In addition, Akt inhibitors could reverse the chemoresistance of sensitive cancer cells induced by exosomes derived from the drug-resistant cells (81). Wang B. et al. found that the IC50 of cisplatin in chemo-sensitive TNBC cells increased 2.24 times after being co-cultured with a chemo-resistant cell line but decreased upon treatment with the compound, Yiqi (82).
Exosome and Tumor Chemotherapy Resistance Markers
Exosomes can be isolated from various biological fluids, such as blood, urine and saliva. The blood of healthy individuals may contain over 2000 trillion exosomes, whereas that of cancer patients contains 4000 trillion exosomes. Thus, tumor cells may produce and secrete more exosomes compared with normal cells, and can be used as potential diagnostic biomarkers (83). Yuwen et al. correlated lower serum levels of exosomal miRNA-146a-5p in patients with advanced NSCLC with a higher recurrence rate (84). In addition, serum exosomal miRNA-146a-5p is a novel biomarker that can be used to predict and monitor cisplatin resistance in NSCLC patients. Likewise, the serum exosomes enrichment of in TAG72 indicates a high probability of 5-FU resistance in CRC cells (85), and that of exosomal miRNA-222-3p predicts gemcitabine sensitivity in NSCLC patients (47). TRPC5 expression in breast cancer tissues and patient response to chemotherapy are significantly correlated with the level of cirExo-TRPC5 in peripheral blood. Since cirExo-TRPCS levels increase after chemotherapy, it can be used as a promising biomarker for the image-based detection of chemo-resistance (86). High expression of GSTP1 in circulating exosomes may indicate an increase of chemo-resistance. A clinical study showed that the level of miRNA-151a in cerebrospinal fluid (CSF)-derived exosomes reflects potential chemo-resistance of glioblastoma multiforme (GBM) patients (87). In addition, Leukemia-derived exosomes induced IL-8 production in bone marrow stromal cells, which can protect acute myeloid leukemia cells from chemotherapy drug induced apoptosis (88). The content of exosomes secreted by tumor cells changes along with the level of cellular stress induced by anticancer therapy, which leads to the metastasis of drug resistant phenotypes in breast cancer (72, 82). This leads to the transfer of drug resistance mediated by exosomes between drug resistant cells and sensitive breast cancer cells (89). Moreover, the selective isolation of circulating subsets of exosomes enriched in tumor sources could effectively improve the sensitivity and specificity of detection (90).
Then, according to the above, we boldly speculate that in the future, it can be separated from various human biological liquids, such as blood, urine and salivary blood, which could directly detect some disease-related exosomes bio-markers, so as to predict the condition and curative effect of patients at this stage. Then, some drugs are used to target the corresponding exosomes to reverse the drug resistance. This may be a simple, convenient and universal treatment in the future.
Conclusion and Prospects
Exosomes mediate intercellular communication in the TME, and can induce drug resistance in tumor cells by transferring specific mRNAs, ncRNAs or proteins (91). The differential expression of these molecules in exosomes are useful clinical markers of tumor drug resistance (92). Therefore, there is a clear need to further elucidate the role of exosomes in tumor drug resistance to improve prognostic prediction and therapeutic efficacy.
Exosomes in the TME have increasingly been identified as the vectors of oncogenesis, drug resistance and metastasis, although the exact pathways and mechanisms involved are still unclear. A deeper understanding of these mechanisms will provide new insights into tumor heterogeneity, and significant differences in the chemotherapeutic responses of individual cancer patients. Furthermore, exosomes are also promising nanocarriers for the targeted delivery of drugs to tumor cells. Given that the prognosis of cancer patients is closely associated with natural or acquired chemo-resistance of the tumor cells, early identification of recalcitrant patients can help formulate individualized optimal treatment regimens. Tumor patients have a higher level of plasmatic exosomes compared with healthy individuals, independently of tumor histology. This difference indicates that exosomes released by tumors during chemotherapy may deliver cytotoxic drugs to healthy organs, thus inducing harmful effects (29, 93, 94). Several ncRNAs that can regulate tumor cell proliferation, metastasis, chemoresistance and recurrence have been identified in recent years. Circulating exosomes that contain cancer-specific miRNAs and lncRNAs are promising diagnostic/prognostic biomarkers and therapeutic targets in cancer, although their underlying mechanisms of action remain to be clarified.
Author Contributions
YF and XL performed the research. HL, YF, and XL designed the research study. PL and YFZ contributed essential reagents or tools. YF, HL, and YC helped to analyze the data. XL wrote the article. YF, ZY, and GL revised the article. ZX modified the language. YBZ provided financial assistance. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by a grant from National Major Science and Technology Projects of Hunan Province (2020JJ4633).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
Thank you to all members of the Yunbin Zhong’s team for your special support.
References
1. Pan BT, Teng K, Wu C, Adam M, Johnstone RM. Electron Microscopic Evidence for Externalization of the Transferrin Receptor in Vesicular Form in Sheep Reticulocytes. J Cell Biol (1985) 101(3):942–8. doi: 10.1083/jcb.101.3.942
2. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle Formation During Reticulocyte Maturation. Association of Plasma Membrane Activities With Released Vesicles (Exosomes). J Biol Chem (1987) 262(19):9412–20.
3. Mohd Ali N, Yeap SK, Ho WY, Boo L, Ky H, Satharasinghe DA, et al. Adipose Mscs Suppress MCF7 and MDA-MB-231 Breast Cancer Metastasis and EMT Pathways Leading to Dormancy via Exosomal-Mirnas Following Co-Culture Interaction. Pharmaceuticals (Basel) (2020) 14(1):8. doi: 10.3390/ph14010008
4. Boriachek K, Islam MN, Moller A, Salomon C, Nguyen NT, Hossain MSA, et al. Biological Functions and Current Advances in Isolation and Detection Strategies for Exosome Nanovesicles. Small (2018) 14(6). doi: 10.1002/smll.201702153
5. Jiang L, Gu Y, Du Y, Liu J. Exosomes: Diagnostic Biomarkers and Therapeutic Delivery Vehicles for Cancer. Mol Pharm (2019) 16(8):3333–49. doi: 10.1021/acs.molpharmaceut.9b00409
6. Yan L, Liu G, Wu X. Exosomes Derived From Umbilical Cord Mesenchymal Stem Cells in Mechanical Environment Show Improved Osteochondral Activity via Upregulation of Lncrna H19. J Orthop Translat (2021) 26:111–20. doi: 10.1016/j.jot.2020.03.005
7. Wang X, Yang G. Bone Marrow Mesenchymal Stem Cells-Derived Exosomes Reduce Abeta Deposition and Improve Cognitive Function Recovery in Mice With Alzheimer’s Disease by Activating Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Pathway. Cell Biol Int (2020) 45(4):775–84. doi: 10.1002/cbin.11522
8. Fenselau C, Ostrand-Rosenberg S. Molecular Cargo in Myeloid-Derived Suppressor Cells and Their Exosomes. Cell Immunol (2021) 359:104258. doi: 10.1016/j.cellimm.2020.104258
9. Bai S, Xiong X, Tang B, Ji T, Li X, Qu X, et al. Exosomal Circ_DLGAP4 Promotes Diabetic Kidney Disease Progression by Sponging MiR-143 and Targeting ERBB3/NF-KappaB/MMP-2 Axis. Cell Death Dis (2020) 11(11):1008. doi: 10.1038/s41419-020-03169-3
10. Yunusova NV, Tugutova EA, Tamkovich SN, Kondakova IV. [The Role of Exosomal Tetraspanins and Proteases in Tumor Progression]. BioMed Khim (2018) 64(2):123–33. doi: 10.18097/PBMC20186402123
11. Tamkovich SN, Yunusova NV, Tugutova E, Somov AK, Proskura KV, Kolomiets LA, et al. Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients. Asian Pac J Cancer Prev (2019) 20(1):255–62. doi: 10.31557/APJCP.2019.20.1.255
12. Miles J, Andre M, Caobi A, Ruiz M, Nair M, Raymond AD. Bioengineered Exosomal Extracellular Vesicles in Cancer Therapeutics. Crit Rev BioMed Eng (2020) 48(3):177–87. doi: 10.1615/CritRevBiomedEng.2020034847
13. Pan S, Zhao X, Shao C, Fu B, Huang Y, Zhang N, et al. STIM1 Promotes Angiogenesis by Reducing Exosomal Mir-145 in Breast Cancer MDA-MB-231 Cells. Cell Death Dis (2021) 12(1):38. doi: 10.1038/s41419-020-03304-0
14. Lin S, Xiong W, Liu H, Pei L, Yi H, Guan Y. Profiling and Integrated Analysis of Differentially Expressed Circular Rnas in Plasma Exosomes as Novel Biomarkers for Advanced-Stage Lung Adenocarcinoma. Onco Targets Ther (2020) 13:12965–77. doi: 10.2147/OTT.S279710
15. McLaughlin M, Patin EC, Pedersen M, Wilkins A, Dillon MT, Melcher AA, et al. Inflammatory Microenvironment Remodelling by Tumour Cells After Radiotherapy. Nat Rev Cancer (2020) 20(4):203–17. doi: 10.1038/s41568-020-0246-1
16. Kim H, Kim EH, Kwak G, Chi SG, Kim SH, Yang Y. Exosomes: Cell-Derived Nanoplatforms for the Delivery of Cancer Therapeutics. Int J Mol Sci (2020) 22(1):14. doi: 10.3390/ijms22010014
17. Ho M, Chen T, Liu J, Dowling P, Hideshima T, Zhang L, et al. Targeting Histone Deacetylase 3 (HDAC3) in the Bone Marrow Microenvironment Inhibits Multiple Myeloma Proliferation by Modulating Exosomes and IL-6 Trans-Signaling. Leukemia (2020) 34(1):196–209. doi: 10.1038/s41375-019-0493-x
18. Li Z, Zhou X, Gao X, Bai D, Dong Y, Sun W, et al. Fusion Protein Engineered Exosomes for Targeted Degradation of Specific Rnas in Lysosomes: A Proof-of-Concept Study. J Extracell Vesicles (2020) 9(1):1816710. doi: 10.1080/20013078.2020.1816710
19. Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, et al. Heat Shock Protein 70 Surface-Positive Tumor Exosomes Stimulate Migratory and Cytolytic Activity of Natural Killer Cells. Cancer Res (2005) 65(12):5238–47. doi: 10.1158/0008-5472.CAN-04-3804
20. Fodor A, Abate BA, Deak P, Fodor L, Gyenge E, Klein MG, et al. Multidrug Resistance (MDR) and Collateral Sensitivity in Bacteria, With Special Attention to Genetic and Evolutionary Aspects and to the Perspectivs of Antimicrobial Peptides-A Review. Pathogens (2020) 9(7):522. doi: 10.3390/pathogens9070522
21. Lin Y, Luo Y, Sun Y, Guo W, Zhao X, Xi Y, et al. Genomic and Transcriptomic Alterations Associated With Drug Vulnerabilities and Prognosis in Adenocarcinoma at the Gastroesophageal Junction. Nat Commun (2020) 11(1):6091. doi: 10.1038/s41467-020-19949-6
22. He L, Chen Y, Ke Z, Pang M, Yang B, Feng F, et al. Exosomes Derived From Mirna-210 Overexpressing Bone Marrow Mesenchymal Stem Cells Protect Lipopolysaccharide Induced Chondrocytes Injury via the NF-KappaB Pathway. Gene (2020) 751:144764. doi: 10.1016/j.gene.2020.144764
23. Zheng X, Liu J, Li X, Tian R, Shang K, Dong X, et al. Angiogenesis Is Promoted by Exosomal DPP4 Derived From 5-Fluorouracil-Resistant Colon Cancer Cells. Cancer Lett (2021) 497:190–201. doi: 10.1016/j.canlet.2020.10.009
24. Ilkhani K, Bastami M, Delgir S, Safi A, Talebian S, Alivand MR. The Engaged Role of Tumor Microenvironment in Cancer Metabolism: Focusing on Cancer-Associated Fibroblast and Exosome Mediators. Anticancer Agents Med Chem (2021) 21(2):254–66. doi: 10.2174/1871520620666200910123428
25. Farc O, Cristea V. An Overview of the Tumor Microenvironment, From Cells to Complex Networks (Review). Exp Ther Med (2021) 21(1):96. doi: 10.3892/etm.2020.9528
26. Kalluri R, LeBleu VS. The Biology, Function, and Biomedical Applications of Exosomes. Science (2020) 367(6478):eaau6977. doi: 10.1126/science.aau6977
27. Logozzi M, Capasso C, Di Raimo R, Del Prete S, Mizzoni D, Falchi M, et al. Prostate Cancer Cells and Exosomes in Acidic Condition Show Increased Carbonic Anhydrase IX Expression and Activity. J Enzyme Inhib Med Chem (2019) 34(1):272–8. doi: 10.1080/14756366.2018.1538980
28. Logozzi M, Mizzoni D, Angelini DF, Di Raimo R, Falchi M, Battistini L, et al. Microenvironmental Ph and Exosome Levels Interplay in Human Cancer Cell Lines of Different Histotypes. Cancers (Basel) (2018) 10(10):370. doi: 10.3390/cancers10100370
29. Logozzi M, De Milito A, Lugini L, Borghi M, Calabro L, Spada M, et al. High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. PloS One (2009) 4(4):e5219. doi: 10.1371/journal.pone.0005219
30. Logozzi M, Angelini DF, Iessi E, Mizzoni D, Di Raimo R, Federici C, et al. Increased PSA Expression on Prostate Cancer Exosomes in In Vitro Condition and in Cancer Patients. Cancer Lett (2017) 403:318–29. doi: 10.1016/j.canlet.2017.06.036
31. Feng C, Xiong Z, Wang C, Xiao W, Xiao H, Xie K, et al. Folic Acid-Modified Exosome-PH20 Enhances the Efficiency of Therapy via Modulation of the Tumor Microenvironment and Directly Inhibits Tumor Cell Metastasis. Bioact Mater (2021) 6(4):963–74. doi: 10.1016/j.bioactmat.2020.09.014
32. Kugeratski FG, Kalluri R. Exosomes as Mediators of Immune Regulation and Immunotherapy in Cancer. FEBS J (2021) 288(1):10–35. doi: 10.1111/febs.15558
33. Qian M, Chen Z, Guo X, Wang S, Zhang Z, Qiu W, et al. Exosomes Derived From Hypoxic Glioma Deliver Mir-1246 and Mir-10b-5p to Normoxic Glioma Cells to Promote Migration and Invasion. Lab Invest (2021) 101(5):612–24. doi: 10.1038/s41374-020-00522-0
34. Yuan X, Qian N, Ling S, Li Y, Sun W, Li J, et al. Breast Cancer Exosomes Contribute to Pre-Metastatic Niche Formation and Promote Bone Metastasis of Tumor Cells. Theranostics (2021) 11(3):1429–45. doi: 10.7150/thno.45351
35. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, et al. Cancer-Secreted MiR-105 Destroys Vascular Endothelial Barriers to Promote Metastasis. Cancer Cell (2014) 25(4):501–15. doi: 10.1016/j.ccr.2014.03.007
36. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell (2000) 100(1):57–70. doi: 10.1016/s0092-8674(00)81683-9
37. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell (2011) 144(5):646–74. doi: 10.1016/j.cell.2011.02.013
38. Torreggiani E, Roncuzzi L, Perut F, Zini N, Baldini N. Multimodal Transfer of MDR by Exosomes in Human Osteosarcoma. Int J Oncol (2016) 49(1):189–96. doi: 10.3892/ijo.2016.3509
39. Kato T, Mizutani K, Kameyama K, Kawakami K, Fujita Y, Nakane K, et al. Serum Exosomal P-Glycoprotein Is a Potential Marker to Diagnose Docetaxel Resistance and Select a Taxoid for Patients With Prostate Cancer. Urol Oncol (2015) 33(9):385.e15–20. doi: 10.1016/j.urolonc.2015.04.019
40. Yuan Y, Wang L, Ge D, Tan L, Cao B, Fan H, et al. Exosomal O-Glcnac Transferase From Esophageal Carcinoma Stem Cell Promotes Cancer Immunosuppression Through Up-Regulation of PD-1 in CD8(+) T Cells. Cancer Lett (2021) 500:98–106. doi: 10.1016/j.canlet.2020.12.012
41. Zhou C, Wei W, Ma J, Yang Y, Liang L, Zhang Y, et al. Cancer-Secreted Exosomal MiR-1468-5p Promotes Tumor Immune Escape via the Immunosuppressive Reprogramming of Lymphatic Vessels. Mol Ther (2020) 29(4):1512–28. doi: 10.1016/j.ymthe.2020.12.034
42. Binenbaum Y, Fridman E, Yaari Z, Milman N, Schroeder A, Ben David G, et al. Transfer of MiRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma. Cancer Res (2018) 78(18):5287–99. doi: 10.1158/0008-5472.CAN-18-0124
43. Qin X, Yu S, Zhou L, Shi M, Hu Y, Xu X, et al. Cisplatin-Resistant Lung Cancer Cell-Derived Exosomes Increase Cisplatin Resistance of Recipient Cells in Exosomal Mir-100-5p-Dependent Manner. Int J Nanomed (2017) 12:3721–33. doi: 10.2147/ijn.S131516
44. Fu X, Liu M, Qu S, Ma J, Zhang Y, Shi T, et al. Exosomal MicroRNA-32-5p Induces Multidrug Resistance in Hepatocellular Carcinoma via the PI3K/Akt Pathway. J Exp Clin Cancer Res (2018) 37(1):52. doi: 10.1186/s13046-018-0677-7
45. Yu DD, Wu Y, Zhang XH, Lv MM, Chen WX, Chen X, et al. Exosomes From Adriamycin-Resistant Breast Cancer Cells Transmit Drug Resistance Partly by Delivering MiR-222. Tumour Biol (2016) 37(3):3227–35. doi: 10.1007/s13277-015-4161-0
46. Zhang S, Zhang Y, Qu J, Che X, Fan Y, Hou K, et al. Exosomes Promote Cetuximab Resistance via the PTEN/Akt Pathway in Colon Cancer Cells. Braz J Med Biol Res (2017) 51(1):e6472. doi: 10.1590/1414-431x20176472
47. Wei F, Ma C, Zhou T, Dong X, Luo Q, Geng L, et al. Exosomes Derived From Gemcitabine-Resistant Cells Transfer Malignant Phenotypic Traits via Delivery of MiRNA-222-3p. Mol Cancer (2017) 16(1):132. doi: 10.1186/s12943-017-0694-8
48. Takahashi K, Yan IK, Kogure T, Haga H, Patel T. Extracellular Vesicle-Mediated Transfer of Long Non-Coding RNA ROR Modulates Chemosensitivity in Human Hepatocellular Cancer. FEBS Open Bio (2014) 4:458–67. doi: 10.1016/j.fob.2014.04.007
49. Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y, et al. Exosome-Transmitted Lncarsr Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA. Cancer Cell (2016) 29(5):653–68. doi: 10.1016/j.ccell.2016.03.004
50. Zheng P, Chen L, Yuan X, Luo Q, Liu Y, Xie G, et al. Exosomal Transfer of Tumor-Associated Macrophage-Derived Mir-21 Confers Cisplatin Resistance in Gastric Cancer Cells. J Exp Clin Cancer Res (2017) 36(1):53. doi: 10.1186/s13046-017-0528-y
51. Ji R, Zhang B, Zhang X, Xue J, Yuan X, Yan Y, et al. Exosomes Derived From Human Mesenchymal Stem Cells Confer Drug Resistance in Gastric Cancer. Cell Cycle (2015) 14(15):2473–83. doi: 10.1080/15384101.2015.1005530
52. Tang JX, Chen Q, Li Q, He YH, Xiao D. Exosomal mRNAs and Lncrnas Involved in Multiple Myeloma Resistance to Bortezomib. Cell Biol Int (2020) 45(5):965–75. doi: 10.1002/cbin.11540
53. Hu Y, Yan C, Mu L, Huang K, Li X, Tao D, et al. Fibroblast-Derived Exosomes Contribute to Chemoresistance Through Priming Cancer Stem Cells in Colorectal Cancer. PloS One (2015) 10(5):e0125625. doi: 10.1371/journal.pone.0125625
54. Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, et al. Exosome Transfer From Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways. Cell (2014) 159(3):499–513. doi: 10.1016/j.cell.2014.09.051
55. Hou Y, Liu Y, Liang S, Ding R, Mo S, Yan D, et al. The Novel Targetexosoms Derived From M2 Macrophage. Int Rev Immunol (2020), 40(3):183–196. doi: 10.1080/08830185.2020.1800687
56. Federici C, Petrucci F, Caimi S, Cesolini A, Logozzi M, Borghi M, et al. Exosome Release and Low Ph Belong to a Framework of Resistance of Human Melanoma Cells to Cisplatin. PloS One (2014) 9(2):e88193. doi: 10.1371/journal.pone.0088193
57. Kusuzaki K, Matsubara T, Murata H, Logozzi M, Iessi E, Di Raimo R, et al. Natural Extracellular Nanovesicles and Photodynamic Molecules: Is There a Future for Drug Delivery? J Enzyme Inhib Med Chem (2017) 32(1):908–16. doi: 10.1080/14756366.2017.1335310
58. Logozzi M, Di Raimo R, Properzi F, Barca S, Angelini DF, Mizzoni D, et al. Nanovesicles Released by OKT3 Hybridoma Express Fully Active Antibodies. J Enzyme Inhib Med Chem (2021) 36(1):175–82. doi: 10.1080/14756366.2020.1852401
59. Logozzi M, Mizzoni D, Capasso C, Del Prete S, Di Raimo R, Falchi M, et al. Plasmatic Exosomes From Prostate Cancer Patients Show Increased Carbonic Anhydrase IX Expression and Activity and Low Ph. J Enzyme Inhib Med Chem (2020) 35(1):280–8. doi: 10.1080/14756366.2019.1697249
60. Logozzi M, Mizzoni D, Bocca B, Di Raimo R, Petrucci F, Caimi S, et al. Human Primary Macrophages Scavenge Aunps and Eliminate It Through Exosomes. A Natural Shuttling for Nanomaterials. Eur J Pharm Biopharm (2019) 137:23–36. doi: 10.1016/j.ejpb.2019.02.014
61. Schott DS, Pizon M, Pachmann U, Pachmann K, Schobert R, Wittig A, et al. Influence of Adjuvant Radiotherapy on Circulating Epithelial Tumor Cells and Circulating Cancer Stem Cells in Primary Non-Metastatic Breast Cancer. Transl Oncol (2021) 14(3):101009. doi: 10.1016/j.tranon.2021.101009
62. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, et al. Embryonic Stem Cell-Derived Microvesicles Reprogram Hematopoietic Progenitors: Evidence for Horizontal Transfer of Mrna and Protein Delivery. Leukemia (2006) 20(5):847–56. doi: 10.1038/sj.leu.2404132
63. You J, Li M, Cao LM, Gu QH, Deng PB, Tan Y, et al. Snail1-Dependent Cancer-Associated Fibroblasts Induce Epithelial-Mesenchymal Transition in Lung Cancer Cells via Exosomes. QJM (2019) 112(8):581–90. doi: 10.1093/qjmed/hcz093
64. Domenis R, Cesselli D, Toffoletto B, Bourkoula E, Caponnetto F, Manini I, et al. Systemic T Cells Immunosuppression of Glioma Stem Cell-Derived Exosomes Is Mediated by Monocytic Myeloid-Derived Suppressor Cells. PloS One (2017) 12(1):e0169932. doi: 10.1371/journal.pone.0169932
65. Bigagli E, Luceri C, Guasti D, Cinci L. Exosomes Secreted From Human Colon Cancer Cells Influence the Adhesion of Neighboring Metastatic Cells: Role of Microrna-210. Cancer Biol Ther (2016) 17(10):1062–9. doi: 10.1080/15384047.2016.1219815
66. Lobb RJ, van Amerongen R, Wiegmans A, Ham S, Larsen JE, Moller A. Exosomes Derived From Mesenchymal Non-Small Cell Lung Cancer Cells Promote Chemoresistance. Int J Cancer (2017) 141(3):614–20. doi: 10.1002/ijc.30752
67. Min H, Sun X, Yang X, Zhu H, Liu J, Wang Y, et al. Exosomes Derived From Irradiated Esophageal Carcinoma-Infiltrating T Cells Promote Metastasis by Inducing the Epithelial-Mesenchymal Transition in Esophageal Cancer Cells. Pathol Oncol Res (2018) 24(1):11–8. doi: 10.1007/s12253-016-0185-z
68. Donnarumma E, Fiore D, Nappa M, Roscigno G, Adamo A, Iaboni M, et al. Cancer-Associated Fibroblasts Release Exosomal Micrornas That Dictate an Aggressive Phenotype in Breast Cancer. Oncotarget (2017) 8(12):19592–608. doi: 10.18632/oncotarget.14752
69. Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, et al. Exosomal Transfer of Stroma-Derived Mir21 Confers Paclitaxel Resistance in Ovarian Cancer Cells Through Targeting APAF1. Nat Commun (2016) 7:11150. doi: 10.1038/ncomms11150
70. Dong H, Wang W, Chen R, Zhang Y, Zou K, Ye M, et al. Exosome-Mediated Transfer of Lncrnasnhg14 Promotes Trastuzumab Chemoresistance in Breast Cancer. Int J Oncol (2018) 53(3):1013–26. doi: 10.3892/ijo.2018.4467
71. Vella LJ, Behren A, Coleman B, Greening DW, Hill AF, Cebon J. Intercellular Resistance to BRAF Inhibition can be Mediated by Extracellular Vesicle-Associated Pdgfrbeta. Neoplasia (2017) 19(11):932–40. doi: 10.1016/j.neo.2017.07.002
72. Lv MM, Zhu XY, Chen WX, Zhong SL, Hu Q, Ma TF, et al. Exosomes Mediate Drug Resistance Transfer in MCF-7 Breast Cancer Cells and a Probable Mechanism Is Delivery of P-Glycoprotein. Tumour Biol (2014) 35(11):10773–9. doi: 10.1007/s13277-014-2377-z
73. Williams MS, Basma NJ, Amaral FMR, Williams G, Weightman JP, Breitwieser W, et al. Targeted Nanopore Sequencing for the Identification of ABCB1 Promoter Translocations in Cancer. BMC Cancer (2020) 20(1):1075. doi: 10.1186/s12885-020-07571-0
74. Ning K, Wang T, Sun X, Zhang P, Chen Y, Jin J, et al. UCH-L1-Containing Exosomes Mediate Chemotherapeutic Resistance Transfer in Breast Cancer. J Surg Oncol (2017) 115(8):932–40. doi: 10.1002/jso.24614
75. Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, et al. Molecular Profiling of Prostate Cancer Derived Exosomes May Reveal a Predictive Signature for Response to Docetaxel. Oncotarget (2015) 6(25):21740–54. doi: 10.18632/oncotarget.3226
76. Wang X, Zhang H, Bai M, Ning T, Ge S, Deng T, et al. Exosomes Serve as Nanoparticles to Deliver Anti-Mir-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer. Mol Ther (2018) 26(3):774–83. doi: 10.1016/j.ymthe.2018.01.001
77. Zhang J, Zhang HD, Yao YF, Zhong SL, Zhao JH, Tang JH. Beta-Elemene Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes. Cell Physiol Biochem (2015) 36(6):2274–86. doi: 10.1159/000430191
78. Cao YL, Zhuang T, Xing BH, Li N, Li Q. Exosomal DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer. Cell Biochem Funct (2017) 35(6):296–303. doi: 10.1002/cbf.3276
79. Liu Y, Song B, Wei Y, Chen F, Chi Y, Fan H, et al. Exosomes From Mesenchymal Stromal Cells Enhance Imatinib-Induced Apoptosis in Human Leukemia Cells via Activation of Caspase Signaling Pathway. Cytotherapy (2018) 20(2):181–8. doi: 10.1016/j.jcyt.2017.11.006
80. Li Y, Liang Y, Sang Y, Song X, Zhang H, Liu Y, et al. MiR-770 Suppresses the Chemo-Resistance and Metastasis of Triple Negative Breast Cancer via Direct Targeting of STMN1. Cell Death Dis (2018) 9(1):14. doi: 10.1038/s41419-017-0030-7
81. Liu X, Jiang T, Li X, Zhao C, Li J, Zhou F, et al. Exosomes Transmit T790M Mutation-Induced Resistance in EGFR-Mutant NSCLC by Activating PI3K/AKT Signalling Pathway. J Cell Mol Med (2020) 24(2):1529–40. doi: 10.1111/jcmm.14838
82. Wang B, Zhang Y, Ye M, Wu J, Ma L, Chen H. Cisplatin-Resistant MDA-MB-231 Cell-Derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal MiR-423-5p-Dependent Manner. Curr Drug Metab (2019) 20(10):804–14. doi: 10.2174/1389200220666190819151946
83. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 Identifies Cancer Exosomes and Detects Early Pancreatic Cancer. Nature (2015) 523(7559):177–82. doi: 10.1038/nature14581
84. Yuwen DL, Sheng BB, Liu J, Wenyu W, Shu YQ. MiR-146a-5p Level in Serum Exosomes Predicts Therapeutic Effect of Cisplatin in Non-Small Cell Lung Cancer. Eur Rev Med Pharmacol Sci (2017) 21(11):2650–8.
85. Kang KW, Jung JH, Hur W, Park J, Shin H, Choi B, et al. The Potential of Exosomes Derived From Chronic Myelogenous Leukaemia Cells as a Biomarker. Anticancer Res (2018) 38(7):3935–42. doi: 10.21873/anticanres.12679
86. Wang T, Ning K, Lu TX, Sun X, Jin L, Qi X, et al. Increasing Circulating Exosomes-Carrying TRPC5 Predicts Chemoresistance in Metastatic Breast Cancer Patients. Cancer Sci (2017) 108(3):448–54. doi: 10.1111/cas.13150
87. Yang SJ, Wang DD, Li J, Xu HZ, Shen HY, Chen X, et al. Predictive Role of GSTP1-Containing Exosomes in Chemotherapy-Resistant Breast Cancer. Gene (2017) 623:5–14. doi: 10.1016/j.gene.2017.04.031
88. Chen T, Zhang G, Kong L, Xu S, Wang Y, Dong M. Leukemia-Derived Exosomes Induced IL-8 Production in Bone Marrow Stromal Cells to Protect the Leukemia Cells Against Chemotherapy. Life Sci (2019) 221:187–95. doi: 10.1016/j.lfs.2019.02.003
89. Dong X, Bai X, Ni J, Zhang H, Duan W, Graham P, et al. Exosomes and Breast Cancer Drug Resistance. Cell Death Dis (2020) 11(11):987. doi: 10.1038/s41419-020-03189-z
90. Foroni C, Zarovni N, Bianciardi L, Bernardi S, Triggiani L, Zocco D, et al. When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients. Biomedicines (2020) 8(5):131. doi: 10.3390/biomedicines8050131
91. Qiao L, Liu X, Tang Y, Zhao Z, Zhang J, Liu H. Knockdown of Long non-Coding RNA Prostate Cancer-Associated Ncrna Transcript 1 Inhibits Multidrug Resistance and C-Myc-Dependent Aggressiveness in Colorectal Cancer Caco-2 and HT-29 Cells. Mol Cell Biochem (2018) 441(1-2):99–108. doi: 10.1007/s11010-017-3177-8
92. Santos JC, Lima NDS, Sarian LO, Matheu A, Ribeiro ML, Derchain SFM. Exosome-Mediated Breast Cancer Chemoresistance via MiR-155 Transfer. Sci Rep (2018) 8(1):829. doi: 10.1038/s41598-018-19339-5
93. Osti D, Del Bene M, Rappa G, Santos M, Matafora V, Richichi C, et al. Clinical Significance of Extracellular Vesicles in Plasma From Glioblastoma Patients. Clin Cancer Res (2019) 25(1):266–76. doi: 10.1158/1078-0432.CCR-18-1941
Keywords: exosomes, cancer, chemoresistance, drug resistance, tumor microenvironment, signal transmission
Citation: Zhong Y, Li H, Li P, Chen Y, Zhang M, Yuan Z, Zhang Y, Xu Z, Luo G, Fang Y and Li X (2021) Exosomes: A New Pathway for Cancer Drug Resistance. Front. Oncol. 11:743556. doi: 10.3389/fonc.2021.743556
Received: 18 July 2021; Accepted: 06 September 2021;
Published: 24 September 2021.
Edited by:
José Díaz-Chávez, National Institute of Cancerology (INCAN), MexicoReviewed by:
Simona Bernardi, University of Brescia, ItalyStefano Fais, National Institute of Health (ISS), Italy
Copyright © 2021 Zhong, Li, Li, Chen, Zhang, Yuan, Zhang, Xu, Luo, Fang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yuan Fang, jingji5996@163.com; Xu Li, 1090787456@qq.com
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally to this work